BNP Paribas Financial Markets lessened its stake in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 69.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,443 shares of the company's stock after selling 132,711 shares during the quarter. BNP Paribas Financial Markets' holdings in HUTCHMED were worth $1,141,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. M&G PLC raised its position in HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company's stock worth $5,345,000 after acquiring an additional 132,333 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of HUTCHMED by 74.8% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock valued at $2,248,000 after purchasing an additional 56,200 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company's stock valued at $952,000 after purchasing an additional 24,245 shares during the period. Crossmark Global Holdings Inc. bought a new position in shares of HUTCHMED in the third quarter valued at about $328,000. Finally, Point72 Asset Management L.P. bought a new position in shares of HUTCHMED in the second quarter valued at about $279,000. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Stock Down 3.8 %
Shares of HCM traded down $0.66 during mid-day trading on Tuesday, reaching $16.88. The company had a trading volume of 47,888 shares, compared to its average volume of 117,345. The company's 50 day simple moving average is $18.70 and its 200 day simple moving average is $18.31. HUTCHMED has a 1-year low of $11.93 and a 1-year high of $21.92. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.
Analysts Set New Price Targets
Separately, StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.
View Our Latest Stock Analysis on HCM
HUTCHMED Company Profile
(
Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
